AGC Biologics to Support Teikoku Seiyaku’s KTP-001
Seattle-based AGC Biologics has been selected by Japanese pharmaceutical company Teikoku Seiyaku to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 being developed to treat lumbar disc herniation.
Under the agreement, initial cell bank creation will take place at AGC Biologics’ Microbial Center of Excellence in Heidelberg, Germany, before the project transitions to the company’s facility in Chiba, Japan, for process development and GMP manufacturing to support clinical trials. “We are delighted to support the Teikoku Seiyaku team on such an innovative project. It’s a privilege to support their vision for a therapy that could offer a new, less invasive option for patients,” said Susumu Zen-In, General Manager of the AGC Biologics Chiba site.
AGC Biologics’ selection highlights the global reach of Washington’s biomanufacturing industry in advancing promising therapies toward clinical use.